Key result
Accufix J atrial leads show ~53% survival with the lead still implanted at 5 years.
Why the study?
Morbidity and mortality have been reported in patients with Accufix J retention wire atrial leads, necessitating ongoing monitoring and lead extractions, but estimating the remaining population at risk is important for patient management guidelines.
What is the probability of remaining free from extraction or death in patients with an Accufix J retention wire atrial permanent pacemaker lead?
Cohort (n=2,298)
Yes
What is the probability of remaining free from extraction or death in patients with an Accufix J retention wire atrial permanent pacemaker lead?
Kaplan-Meier estimates of event-free survival can help guide management decisions regarding extraction versus monitoring for patients with Accufix J retention wire atrial leads.
May inform extraction decisions in Accufix leads; leaves open randomized trials of management strategies.
UNLABELLED: Morbidity (36 cases) and mortality (6 cases) have been reported in patients with Accufix J retention wire atrial leads. This has resulted in ongoing patient fluoroscopic monitoring as well as lead extractions. The estimated implanted worldwide population is 40,860. Estimating the size of the remaining population at risk is an important tool for assessing patient management guidelines. RESULTS: The Kaplan-Meier method can be used to calculate the cumulative probability of remaining free of extraction and death for patients based on implant duration. The individual Kaplan-Meier curves for lead extraction and patient survival can also be computed. Based on the Multicenter Study (MCS) population of 2,298 patients, the probability that a patient is alive with the lead still implanted at 5 years implant duration is 52.5%. The event-free survival rate at 5 years implant duration is 81.3%. The corresponding probability of remaining free from injury due to the J-wire is 99.9% at 5 years implant duration. Assuming similar rates of death and extraction, these results can be extrapolated to the world wide population. CONCLUSIONS: The management of Accufix patients must consider patient longevity, the probability of J-wire morbidity/mortality, and the probability of extraction complication morbidity/mortality. The probability of remaining at risk as a function of time from implant can be calculated from the events known in the MCS patient population. These event-free survival estimates can be used to identify subsets of the population at greater or lesser risk based on various clinical parameters.
No takes yet. Share an insight, caveat, or question.
Kawanishi et al. (1998) conducted a cohort in Accufix J retention wire atrial permanent pacemaker lead (n=2,298). Accufix J retention wire atrial permanent pacemaker lead was evaluated on Alive with the lead still implanted (freedom from extraction or death). In patients with an Accufix J retention wire atrial lead, the probability of remaining alive with the lead implanted at 5 years was 52.5%, with an event-free survival rate of 81.3%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: